Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients wit...

ver descrição completa

Detalhes bibliográficos
Autores: Ubals, Maria|||0000-0003-1394-197X, Bosch-Nicolau, Pau|||0000-0002-7435-1829, Sánchez Montalvá, Adrián|||0000-0002-2194-5447, Salvador Velez, Fernando Maria|||0000-0002-0546-1354, Aparicio, Gloria|||0000-0001-6878-3353, Sulleiro, Elena|||0000-0002-9783-6060, Silgado, Aroa|||0000-0001-7581-0049, Soriano-Arandes, Antoni|||0000-0001-9613-7228, Espiau, María|||0000-0001-9697-7649, Ferrer, Berta|||0000-0002-1255-4647, Pou, Diana|||0000-0003-0230-6241, Treviño Maruri, Begoña|||0000-0003-4633-8288, Molina Romero, Israel|||0000-0001-6642-7515, García-Patos Briones, Vicente|||0000-0003-1654-6035
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:293123
Acesso em linha:https://ddd.uab.cat/record/293123
https://dx.doi.org/urn:doi:10.3390/pathogens10101253
Access Level:acceso abierto
Palavra-chave:Complex cutaneous leishmaniasis
Cutaneous leishmaniasis
Leishmania
Liposomal amphotericin B
Systemic therapy
Descrição
Resumo:There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.

Registos relacionados